

DISCLAIMER

This Molina Clinical Policy (MCP) is intended to facilitate the Utilization Management process. Policies are not a supplementation or recommendation for treatment; Providers are solely responsible for the diagnosis, treatment, and clinical recommendations for the Member. It expresses Molina's determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (e.g., will be paid for by Molina) for a particular Member. The Member's benefit plan determines coverage – each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their Providers will need to consult the Member's benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a Member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid Members. CMS's Coverage Database can be found on the CMS website. The coverage directive(s) and criteria from an existing National Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this MCP and provide the directive for all Medicare members. References included were accurate at the time of policy approval and publication.

OVERVIEW

There are several ambulatory cardiac rhythm monitoring devices on the market. This policy is only applicable to mobile cardiac outpatient telemetry.

Cardiac Arrhythmias cause significant morbidity and mortality. While many cardiac arrhythmias can be captured on short term electrocardiograms (ECG) some, such as paroxysmal atrial fibrillation, can be missed on routine ECGs, thus needing long term telemetry to be captured, diagnosed, and treated.

Mobile Cardiac Outpatient Telemetry (MCOT) is used for evaluation of suspected non-life-threatening arrhythmias that have not been detected by office or hospital-based monitoring. A wearable mobile device provides real-time tracing of a patient's heart rhythm. When significant arrhythmias are detected, the monitor automatically transmits the patient's ECG data via a wireless network to the central monitoring station, which is attended by trained technicians 24 hours per day. This offers the potential for immediate evaluation by a healthcare provider.

Regulatory Status

The U.S. Food and Drug Administration (FDA) has cleared several MCOT devices. The following list is not exhaustive, and the current status of the requested MCOT should be verified on the FDA website (product codes: DSI, DXH):

- CardioNet MCOT™ System (CardioNet)
- HEARTLink II™ System (Cardiac Telecom Corp.)
- Heartrak Smart External Cardiac Ambulatory Telemetry System (Mednet Healthcare Technologies, Inc.)
- LifeWatch™ Ambulatory Cardiac Telemetry (ACT) System (LifeWatch Inc.)
- TruVue® Wireless Ambulatory Monitoring Systems (Biomedical Systems)
- VST3™ Vital Signs Transmitter (Biowatch Medical Inc.)

Specific brand names are used for illustrative purposes only and is not intended to be a recommendation of one product over another, nor a comprehensive list of all accessible products.

RELATED POLICIES

This policy does not apply to requests for services as part of a surveillance protocol for members engaging in a clinical trial. Refer to *Clinical Trials and Rare Disease: Policy No. 183*.

COVERAGE POLICY

Mobile cardiac outpatient telemetry (MCOT) may be **considered medically necessary** when **ALL** the following criteria are met:

1. Prescribed by a qualified physician with clinical experience and training in cardiac telemetry for **ONE** of the following indications:
 - a. Member requires monitoring for known non-life-threatening arrhythmias such as paroxysmal atrial fibrillation, other paroxysmal supraventricular arrhythmias, brady-arrhythmias, or intermittent bundle branch block with no prior cardiac telemetry done within the last 3 months
 - b. Member is recovering from cardiac surgery and has documented atrial arrhythmias with no prior *outpatient* cardiac telemetry done since cardiac surgery
 - c. Member presents with recurrent severe symptoms (i.e., recurrent syncope or presyncope) with no prior cardiac telemetry done within the last 3 months
2. Submission is accompanied by **ALL** the following clinical documentation supporting the medical necessity of the telemetry:
 - a. Progress note(s) from a cardiologist or electrophysiologist that prompted the request for a MCOT
 - b. Recent EKG (within 10 days), if available
 - c. Most recent Holter or event monitor or device interrogation report, if available

Limitations and Exclusions

The following are considered **experimental, investigational, and unproven** based on insufficient evidence:

1. Any indications other than those listed above.
Cases where a hospital setting may be more suitable or inpatient monitoring is required:
 - a. Potentially life-threatening arrhythmias
 - b. Patients deemed by the attending physician to require hospitalization
 - c. High-risk of developing sustained ventricular tachycardia or ventricular fibrillation
2. Concurrent or prior use of other cardiac surveillance services or cardiac telemetry (e.g., ECG, Holter monitor, or other event recorder) has provided clinical data or information, and MCOT is not expected to provide the data/information required for the diagnosis and/or treatment of the patient's condition/symptoms
3. Prescribed primarily for the daily transmission of ECG rhythm strips or telemetry recordings in the absence of symptoms requiring diagnosis/treatment

Coverage Limitations

Real-time cardiac telemetry is a service that lasts **up to 30 days** and is used to diagnose or suspected and/or paroxysmal dysrhythmia. Generally, continuing testing for more than 30 days is not medically necessary. In most cases, failure to detect a dysrhythmia after a 30-day monitoring period does not necessitate further testing.

EXCEPTION: Monitoring for longer than 30 days is only medically necessary in exceptional circumstances and must be justified by the treating physician/provider with supporting documentation for review.

DOCUMENTATION REQUIREMENTS. Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational, or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive.

SUMMARY OF MEDICAL EVIDENCE

Randomized Controlled Trials

Rothman et al. (2007) conducted a multicenter RCT that compared MCOT to the standard patient-activated external loop event monitoring to monitor patients who had palpitations, presyncope, syncope or a combination of these symptoms. All participants had a high clinical suspicion of malignant arrhythmia, symptoms of syncope, pre-syncope or severe palpitations occurring less frequently than once every 24 hours, and a nondiagnostic 24-hour Holter or telemetry monitor within 48 days prior to enrollment. All 266 participants (n=266) were randomly assigned to either MCOT or an external loop monitor for 30 days. The primary endpoint was either the confirmation or exclusion of an arrhythmic cause for the patient's symptoms. Arrhythmias were classified as either clinically significant or clinically insignificant. A diagnosis was made in 88% of the MCOT group and 75% of the loop event monitoring group. There was no significant difference between MCOT and external loop event monitoring in their ability to detect or exclude a cardiac arrhythmia occurring simultaneously with the symptoms (arrhythmia occurred simultaneously with symptoms in 40% and 47% in the two groups respectively in all patients with arrhythmia, and 42% and 40% respectively for patients with syncope/presyncope. The authors also noted that the MCOT system (CardioNet, USA) was compared to patient-activated external event recorders with looping and the study did not compare MCOT to implanted loop recorders, nor was it designed to compare it to auto-trigger loop recorders, which were used in only 16% of the external loop event monitoring group's patients. The authors concluded that outpatient telemetry system may detect more arrhythmias than external loop recorders in patients with syncope or presyncope.

Systematic Reviews and Meta-Analyses

Jiang et al. (2022) conducted a systematic retrospective review of all randomized controlled trials and prospective cohort studies investigating the use of extended ECG monitoring >24 hours for the detection of atrial fibrillation (AF) following cryptogenic stroke. Researchers reviewed a total of 3458 studies, with 47 studies selected for further analysis. These studies represented 6448 post-cryptogenic stroke patients who were evaluated for AF utilizing either implantable loop recorders or MCOT from January 2011 to November 2021. While historically implantable loop recorders were considered the gold standard of ECG monitoring, implantable loop recorders involve an invasive procedure requiring patient compliance for long-term follow-up and are more costly than MCOT. This meta-analysis found that systematic reviews of MCOT after cryptogenic stroke were limited and often did not provide comparison to implantable loop recorders. Another factor identified was the wide variety of MCOT device types including wireless recorders (52.9%), chest belts (29.4%), patches ((17.6%), and handheld devices (17.6%). Researchers concluded that patient compliance is one of the main factors limiting the use of MCOTs due to the reliance on daily or more frequent application. Patient poststroke neurological disability also excluded some users from eligibility for MCOT devices due to insufficient cognitive and physical ability. Researchers concluded that appropriate device selection for ECG monitoring requires that the clinician consider patient clinical judgement and preference, duration of monitoring, and overall cost as components of treatment recommendations. Further research with specific criteria and comparison of device types is needed regarding the use of MCOT for detection of AF in patients with cryptogenic stroke.

Sposato et al. (2015) conducted a systematic review and meta-analysis of 50 studies (n = 11,658) to estimate the proportion of individuals with newly diagnosed AF following transient ischemic attack (TIA) or stroke. The studies noted diagnostic methods including ECG, continuous inpatient ECG monitoring, Holter monitoring, continuous inpatient cardiac telemetry, outpatient MCOT, external loop recording and implantable loop recorders. Phase 1 was assessment in the emergency room with ECG. Phase 2 (inpatient stay) comprised serial ECG, continuous ECG, inpatient cardiac telemetry and inpatient Holter monitoring. In phase 3, the first ambulatory period, Holter monitoring was utilized. The fourth phase was the second ambulatory period, which consisted of MCOT, external loop and implantable loop recording. Phase 4 revealed AF in 16.9% of patients. The overall AF detection yield after all phases of sequential cardiac monitoring was 23.7% (95% CI, 17.2% to 31.0%). In phase 4, there were no differences between the proportion of patients diagnosed with post-stroke AF by MCOT (15.3%), ELR (16.2%), or ILR (16.9%). In addition, only around 40% of patients persisted into phase 4 for further surveillance after phase 3. Age and risk variables for post-stroke AF differed throughout the 50 studies. This analysis suggests that extended outpatient MCOT detects post-stroke AF, however the proportion of patients diagnosed in phase 4 by implanted loop recording did not differ significantly from those diagnosed by mobile cardiac outpatient telemetry or external loop recording.

Molina Clinical Policy
Mobile Cardiac Outpatient Telemetry
Policy No. 428

Last Approval: 10/09/2024
Next Review Due By: October 2025



National and Specialty Organizations

The **American Heart Association (AHA) / American Stroke Association (ASA) 2021 AHA/ASA Guidelines for Prevention of Stroke in Patients with Ischemic Stroke or TIA** recommend the following for detection of occult AF (Kleindorfer et al. 2021):

In patients with cryptogenic stroke who do not have a contraindication to anticoagulation, long-term rhythm monitoring with mobile cardiac outpatient telemetry, implantable loop recorder, or other approach is reasonable to detect intermittent AF (Class 2a, Level of Evidence B-R).

The **American College of Cardiology (ACC) / American Heart Association (AHA) / Heart Rhythm Society (HRS)** guidelines on the evaluation and management of patients with syncope address several ambulatory ECG monitoring options (Shen et al. 2017). The guidelines recommend that the duration and type of monitoring system be determined by the frequency and nature of syncope events. The following external cardiac monitoring approaches can be useful in evaluating selected ambulatory patients with syncope of suspected arrhythmic etiology:

- Holter monitor
- Transtelephonic monitor
- External loop recorder
- Patch recorder
- Mobile cardiac outpatient telemetry

Class 2a, Level B-NR (Class 2a: It is reasonable to perform procedure. Level of Evidence B-NR: Based on moderate-quality evidence from one or more well-designed, well-executed nonrandomized, observational or registry studies).

The **National Institute for Health and Care Excellence (NICE)**, in the 2021 guideline on the diagnosis and management of atrial fibrillation, recommends for patients with suspected paroxysmal atrial fibrillation that is not detected with a 12-lead electrocardiogram:

- use a 24-hour ambulatory ECG monitor if asymptomatic episodes are suspected or symptomatic episodes are less than 24 hours apart
- use an ambulatory ECG monitor, event recorder or other ECG technology for a period appropriate to detect atrial fibrillation if symptomatic episodes are more than 24 hours apart.

CODING & BILLING INFORMATION

CPT (Current Procedural Terminology)

Code	Description
93228	External mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real time data analysis and greater than 24 hours of accessible ECG data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30 days; review and interpretation with report by a physician or other qualified health care professional **Note: CPT codes (93228 and 93229) can only be reported once per 30 days of service.
93229	External mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real time data analysis and greater than 24 hours of accessible ECG data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30 days; technical support for connection and patient instructions for use, attended surveillance, analysis and transmission of daily and emergent data reports as prescribed by a physician or other qualified health care professional **Note: CPT codes (93228 and 93229) can only be reported once per 30 days of service.

CODING DISCLAIMER. Codes listed in this policy are for reference purposes only and may not be all-inclusive. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement. Listing of a service or device code in this policy does not guarantee coverage. Coverage is determined by the benefit document. Molina adheres to Current Procedural Terminology (CPT®), a registered

Molina Clinical Policy

Mobile Cardiac Outpatient Telemetry

Policy No. 428

Last Approval: 10/09/2024

Next Review Due By: October 2025



trademark of the American Medical Association (AMA). All CPT codes and descriptions are copyrighted by the AMA; this information is included for informational purposes only. Providers and facilities are expected to utilize industry standard coding practices for all submissions. When improper billing and coding is not followed, Molina has the right to reject/deny the claim and recover claim payment(s). Due to changing industry practices, Molina reserves the right to revise this policy as needed.

APPROVAL HISTORY

10/09/2024	Policy reviewed, no changes to criteria. IRO Peer Review on September 6, 2024, by a practicing physician board-certified in Internal Medicine; Cardiovascular Disease; Interventional Cardiology.
12/13/2023	Policy reviewed, no changes to criteria, updated references.
12/14/2022	New policy.

REFERENCES

1. Jiang H, Tan SY, Wang JK, et al. A meta-analysis of extended ECG monitoring in detection of atrial fibrillation in patients with cryptogenic stroke. *Open Heart*. 2022 Sep;9(2):e002081. doi: 10.1136/openhrt-2022-002081. PMID: 36175044; PMCID: PMC9528717.
2. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association/American Stroke Association. *Stroke*. 2021 Jul;52(7):e364-e467. doi: 10.1161/STR.0000000000000375. Epub 2021 May 24. Erratum in: *Stroke* 2021 Jul;52(7):e483-e484. PMID: 34024117.
3. National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management [NPG196]. Published: April 27, 2021. Updated June 30, 2021. Accessed September 1, 2024. <https://www.nice.org.uk/guidance>
4. Olson JA, Fouts AM, Padanilam BJ, Prystowsky EN. Utility of mobile cardiac outpatient telemetry for the diagnosis of palpitations, presyncope, syncope, and the assessment of therapy efficacy. *J Cardiovasc Electrophysiol*. 2007 May;18(5):473-7. doi: 10.1111/j.1540-8167.2007.00779.x. Epub 2007 Mar 6. PMID: 17343724.
5. Reynbakh O, Braunstein ED, Hsu M, et al. Arrhythmia patterns during and after hospitalization for COVID-19 infection detected via patch-based mobile cardiac telemetry. *Am Heart J Plus*. 2022 Jan;13:100084. doi: 10.1016/j.ahjo.2022.100084. Epub 2022 Jan 10. PMID: 35036973; PMCID: PMC8744398.
6. Rothman, SA., Laughlin, JC., Seltzer, J., et al. The diagnosis of cardiac arrhythmias: a prospective multi-center randomized study comparing mobile cardiac outpatient telemetry versus standard loop event monitoring. *J Cardiovasc Electrophysiol*. 2007 Mar;18(3):241-7. doi: 10.1111/j.1540-8167.2006.00729.x. PMID: 17318994.
7. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. 2017 Aug 1;70(5):e39-e110. PMID: 28286222.
8. Sposato LA, Cipriano LE, Saposnik G, et al. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: A systematic review and meta-analysis. *Lancet Neurol*. Apr 2015; 14(4): 377-87. PMID 25748102
9. United States Food and Drug Administration (FDA). Ambulatory ECG monitor with arrhythmia detection. CardioNet MCOT. No. K093288. Notice of Approval April 08, 2010. Accessed August 30, 2024. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm>.
10. United States Food and Drug Administration (FDA). Ambulatory ECG monitor with arrhythmia detection. HEARTLINK, Model II. No. K982803. Notice of Approval November 13, 1998. Accessed August 30, 2024. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm>.
11. United States Food and Drug Administration (FDA). Arrhythmia detector and alarm. LifeWatch Mobile Cardiac Telemetr 3 Lead. No. K170565. Notice of Approval August 01, 2017. Accessed August 30, 2024. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm>.
12. United States Food and Drug Administration (FDA). Arrhythmia detector and alarm. TruVue Wireless Ambulatory ECG Monitoring System. No. K100155. Notice of Approval April 20, 2010. Accessed August 30, 2024. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm>.
13. United States Food and Drug Administration (FDA). Transmitters and receivers, electrocardiograph, telephone. HEARTRAK SMART AT/HEARTRAK SMART2. No. K033451. Notice of Approval February 05, 2004. Accessed August 30, 2024. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm>.
14. United States Food and Drug Administration (FDA). Transmitters and receivers, electrocardiograph, telephone. VST3, Biowatch Medical, Inc. No. K040942. Notice of Approval September 15, 2004. Accessed August 30, 2024. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm>.